6 completed, 5 terminated, 1 recruiting, 1 unknown. 13 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Completed 6, Terminated 5, Recruiting 1, Unknown 1 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
Follow Simulect: new trials by email Literature Review of Simulect trials Research Report on Simulect
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma Basiliximab, Carmustine, Cytarabine - Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 33 | 2021-11-02 | 2025-12-04 |
| Exploratory Regimen of Basiliximab for Treatment of Pulmonary Cytokine Storm in SARS-CoV-2 Hospitalized Adult Patients Basiliximab Injection, Placebo - SARS-CoV-2 Acute Respiratory Disease, SARS-CoV2 Infection | Phase 2 | Unknown | Fort Worth Clinical Sciences Working Group | 300 | 2021-10-15 | 2021-08-19 |
| Immunosuppression in Amyotrophic Lateral Sclerosis (ALS) Basiliximab, Methylprednisolone, Prednisone - Amyotrophic Lateral Sclerosis (ALS) | Phase 2 | Completed | Emory University | 31 | 2013-10-01 | 2017-11-06 |
| Infliximab and Basiliximab for Treatment of Steroid Refractory Acute Graft Versus Host Disease Infliximab and Basiliximab - Graft Versus Host Disease, Steroid Refractory GVHD | Phase 2 | Terminated | Nationwide Children's Hospital | 11 | 2011-12-01 | 2019-04-05 |
| Campath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy Alemtuzumab, Basiliximab, Sirolimus - Kidney Transplantation | Phase 2 / Phase 3 | Completed | University of Oxford | 852 | 2010-09-01 | 2020-04-02 |
| Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer Basiliximab - Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia | Phase 2 | Completed | Indiana University | 17 | 2009-09-01 | 2016-02-26 |
| Study to Evaluate the Safety of Chronic Administration of Simulect to Subjects Receiving a First Kidney Transplant basiliximab - End Stage Renal Disease | Phase 2 / Phase 3 | Terminated | Drexel University College of Medicine | 5 | 2009-05-01 | 2015-02-10 |
| LEA29Y (Belatacept) Emory Edmonton Protocol Allogeneic Pancreatic Islet Cells, Belatacept, Basiliximab - Type 1 Diabetes Mellitus | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 10 | 2008-10-01 | 2016-04-07 |
| The Safety and Efficacy of Basiliximab as Maintenance Therapy in Subjects With Stable, Noninfectious Uveitis Basiliximab, Placebo - Non-infectious Uveitis | Phase 2 | Terminated | Cerimon Pharmaceuticals | 5 | 2008-05-01 | 2010-08-19 |
| A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients Alefacept, tacrolimus, basiliximab - Kidney Transplantation | Phase 2 | Completed | Astellas Pharma Inc | 323 | 2008-02-01 | 2015-12-11 |
| Basiliximab Maintenance in Ulcerative Colitis Basiliximab - Ulcerative Colitis | Phase 2 | Terminated | Cerimon Pharmaceuticals | 88 | 2007-07-01 | 2010-02-04 |
| Basiliximab in Moderate to Severe Ulcerative Colitis Basiliximab - Ulcerative Colitis | Phase 2 | Completed | Cerimon Pharmaceuticals | 181 | 2007-01-01 | 2008-12-18 |
| Steroid Withdrawal in Pediatric Kidney Transplant Recipients Basiliximab, Cyclosporine, Tacrolimus - End-Stage Renal Disease | Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 274 | 2001-01-01 | 2016-10-21 |
Colitis, Ulcerative (2) · Hodgkin Disease (2) · Kidney Failure, Chronic (2) · Amyotrophic Lateral Sclerosis (1) · Anemia, Aplastic (1) · Anemia, Refractory, with Excess of Blasts (1) · COVID-19 (1) · Cytokine Release Syndrome (1) · Diabetes Mellitus, Type 1 (1) · Graft vs Host Disease (1) · Hemoglobinuria, Paroxysmal (1) · Hypoglycemia (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1)
Cerimon Pharmaceuticals (3) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Astellas Pharma Inc (1) · City of Hope Medical Center (1) · Drexel University College of Medicine (1) · Emory University (1) · Fort Worth Clinical Sciences Working Group (1) · Indiana University (1) · Nationwide Children's Hospital (1) · University of Oxford (1)
United States (10) · United Kingdom (3) · Belgium (1) · Canada (1) · Czechia (1) · India (1) · Mexico (1) · Poland (1) · Russia (1) · Slovakia (1) · Ukraine (1)
A.M. James Shapiro, MD, PhD (1) · Alex F Herrera (1) · Christina N Fournier, MD (1) · Colin Baigent (1) · Daniel Levitt, MD, PhD (1) · Jonathan D Glass, MD (1) · Martin J Landray (1) · Mysore Anil S. Kumar, MD (1) · Nicole Turgeon, MD (1) · Paul Harden (1) · Peter Friend (1) · Rajinder S Bajwa, MD (1) · Richard Haynes (1) · Robert Nelson, MD (1)
PMID 18416737, PMID 19663893, PMID 22549092, PMID 23438305, PMID 23641902, PMID 25078310, PMID 29226570, PMID 29308669
2008 (1), P30CA033572 (1), P50CA107399 (1)